512 related articles for article (PubMed ID: 27918305)
21. Novel Furocoumarin Derivatives Stimulate Melanogenesis in B16 Melanoma Cells by Up-Regulation of MITF and TYR Family via Akt/GSK3β/β-Catenin Signaling Pathways.
Niu C; Yin L; Aisa HA
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29509689
[TBL] [Abstract][Full Text] [Related]
22. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
24. GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes.
Bellei B; Flori E; Izzo E; Maresca V; Picardo M
Cell Signal; 2008 Oct; 20(10):1750-61. PubMed ID: 18602000
[TBL] [Abstract][Full Text] [Related]
25. Uncoupling of ER/Mitochondrial Oxidative Stress in mTORC1 Hyperactivation-Associated Skin Hypopigmentation.
Yang F; Yang L; Wataya-Kaneda M; Yoshimura T; Tanemura A; Katayama I
J Invest Dermatol; 2018 Mar; 138(3):669-678. PubMed ID: 29080681
[TBL] [Abstract][Full Text] [Related]
26. Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα).
Dan HC; Ebbs A; Pasparakis M; Van Dyke T; Basseres DS; Baldwin AS
J Biol Chem; 2014 Sep; 289(36):25227-40. PubMed ID: 24990947
[TBL] [Abstract][Full Text] [Related]
27. Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis.
Zech R; Kiontke S; Mueller U; Oeckinghaus A; Kümmel D
J Biol Chem; 2016 Sep; 291(38):20008-20. PubMed ID: 27493206
[TBL] [Abstract][Full Text] [Related]
28. Andrographolide suppresses melanin synthesis through Akt/GSK3β/β-catenin signal pathway.
Zhu PY; Yin WH; Wang MR; Dang YY; Ye XY
J Dermatol Sci; 2015 Jul; 79(1):74-83. PubMed ID: 25869056
[TBL] [Abstract][Full Text] [Related]
29. The ion channel activator CyPPA inhibits melanogenesis via the GSK3β/β-catenin pathway.
Noh TK; Bang SH; Lee YJ; Cho HI; Jung MY; Kim I; Leem CH; Chang SE
Chem Biol Interact; 2019 Feb; 300():1-7. PubMed ID: 30597128
[TBL] [Abstract][Full Text] [Related]
30. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
[TBL] [Abstract][Full Text] [Related]
31. Aberrant beta-catenin signaling in tuberous sclerosis.
Mak BC; Kenerson HL; Aicher LD; Barnes EA; Yeung RS
Am J Pathol; 2005 Jul; 167(1):107-16. PubMed ID: 15972957
[TBL] [Abstract][Full Text] [Related]
32. GSK-3β-Targeting Fisetin Promotes Melanogenesis in B16F10 Melanoma Cells and Zebrafish Larvae through β-Catenin Activation.
Molagoda IMN; Karunarathne WAHM; Park SR; Choi YH; Park EK; Jin CY; Yu H; Jo WS; Lee KT; Kim GY
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31906440
[TBL] [Abstract][Full Text] [Related]
33. Monoallelic germline TSC1 mutations are permissive for T lymphocyte development and homeostasis in tuberous sclerosis complex individuals.
Pilipow K; Basso V; Migone N; Mondino A
PLoS One; 2014; 9(3):e91952. PubMed ID: 24633152
[TBL] [Abstract][Full Text] [Related]
34. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
35. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of ERK1/2 Restores GSK3β Activity and Protein Synthesis Levels in a Model of Tuberous Sclerosis.
Pal R; Bondar VV; Adamski CJ; Rodney GG; Sardiello M
Sci Rep; 2017 Jun; 7(1):4174. PubMed ID: 28646232
[TBL] [Abstract][Full Text] [Related]
37. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
Zhang HH; Huang J; Düvel K; Boback B; Wu S; Squillace RM; Wu CL; Manning BD
PLoS One; 2009 Jul; 4(7):e6189. PubMed ID: 19593385
[TBL] [Abstract][Full Text] [Related]
38. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis.
Costa V; Aigner S; Vukcevic M; Sauter E; Behr K; Ebeling M; Dunkley T; Friedlein A; Zoffmann S; Meyer CA; Knoflach F; Lugert S; Patsch C; Fjeldskaar F; Chicha-Gaudimier L; Kiialainen A; Piraino P; Bedoucha M; Graf M; Jessberger S; Ghosh A; Bischofberger J; Jagasia R
Cell Rep; 2016 Apr; 15(1):86-95. PubMed ID: 27052171
[TBL] [Abstract][Full Text] [Related]
39. mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition.
Bhaskar PT; Nogueira V; Patra KC; Jeon SM; Park Y; Robey RB; Hay N
Mol Cell Biol; 2009 Sep; 29(18):5136-47. PubMed ID: 19620286
[TBL] [Abstract][Full Text] [Related]
40. Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.
Nathan N; Keppler-Noreuil KM; Biesecker LG; Moss J; Darling TN
Dermatol Clin; 2017 Jan; 35(1):51-60. PubMed ID: 27890237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
